
|Videos|April 19, 2022
Investigational Agents and Unmet Needs in Myelofibrosis Treatment
Author(s)Naveen Pemmaraju, MD
Dr Naveen Pemmaraju discusses exciting potential treatment options in myelofibrosis and some unmet needs and ongoing challenges in the treatment landscape.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Behind the FDA Approval: Isatuximab On-Body Injector Supports ‘Patient-Centric’ Priorities in Multiple Myeloma
2
Safusidenib Shows Durable Responses in IDH1-Mutant Glioma at 3-Year Follow-Up
3
De-Escalated Neoadjuvant HER2-Targeted Therapy Shows Durable 5-Year Survival
4
CheckMate 9LA Data Push Toward Dual Checkpoint Blockade in PD-L1–Negative NSCLC
5

























